Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.
- 16 Aug 2017 Planned initiation date changed from 31 May 2017 to 1 Sep 2017.
- 01 May 2017 Planned initiation date changed from 1 Mar 2017 to 31 May 2017.